Home > Insider Trading > Filing (0001104659-13-041515)

Filing Details

Accession Number:: 0001104659-13-041515
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-05-14 17:32:35
Reporting Period:: 2013-05-14

Filing Date:: 2013-05-14
Accepted Time:: 2013-05-14 17:32:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1463729	Receptos Inc.	RCPT	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1205903	H William Rastetter	10835 Road To The Cure, Suite 205 San Diego CA 92121		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-05-14	113,505	$5.25	193,777	No	4	C	Direct
Common Stock	Acquisiton	2013-05-14	67,029	$7.73	260,806	No	4	C	Direct
Common Stock	Acquisiton	2013-05-14	71,428	$14.00	71,428	No	4	P	Indirect	By Trust
Common Stock	Acquisiton	2013-05-14	1,152,038	$5.25	1,266,322	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2013-05-14	550,872	$7.73	1,817,194	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2013-05-14	265,567	$14.00	2,082,761	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Direct
No	4	P	Indirect	By Trust
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2013-05-14	851,291	$0.00	113,505	$5.25
Common Stock	Series B Preferred Stock	Disposition	2013-05-14	502,720	$0.00	67,029	$7.73
Common Stock	Series A Preferred Stock	Disposition	2013-05-14	8,640,289	$0.00	1,152,038	$5.25
Common Stock	Series B Preferred Stock	Disposition	2013-05-14	4,131,552	$0.00	550,872	$7.73

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Beneficial ownership consists of: (i) 342,741 shares of common stock held by Venrock Associates V, L.P. ("Venrock Associates"); (ii) 29,058 shares of common stock held by Venrock Partners V, L.P. ("Venrock Partners"); (iii) 8,052 shares of common stock held by Venrock Entrepreneurs Fund V, L.P. ("Venrock Entrepreneurs"); (iv) an aggregate of 1,536,537 shares of common stock issued upon conversion of shares of Series A preferred stock and Series B preferred stock held by Venrock Associates; (v) an aggregate of 130,272 shares of common stock issued upon conversion of shares of Series A preferred stock and Series B preferred stock held by Venrock Partners; and (vi) an aggregate of 36,101 shares of common stock issued upon conversion of shares of Series A preferred stock and Series B preferred stock held by Venrock Entrepreneurs.
The sole general partner of Venrock Associates is Venrock Management V, LLC ("Venrock Management V"). The sole general partner of Venrock Partners is Venrock Partners Management V, LLC ("Venrock Partners Management V"). The sole general partner of Venrock Entrepreneurs is VEF Management V, LLC ("VEF"). Venrock Management V, Venrock Partners Management V and VEF disclaim beneficial ownership over all shares held by Venrock Associates, Venrock Partners and Venrock Entrepreneurs, except to the extent of any pecuniary interest therein. Dr. Rastetter was formerly a consultant of an entity affiliated with the Venrock entities but does not have voting or investment control over the shares held by the Venrock entities. Dr. Rastetter has an indirect pecuniary interest in the investment held by the Venrock entities and expressly disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest therein.
The Series A Preferred Stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of Common Stock for every 7.5 shares of Series A Preferred Stock, for no additional consideration.